September 7, 2021

Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients

Structured PICO

Does ticagrelor improve inflammatory parameters (NLR, MHR, PLR, and SII) in PCI-treated ACS patients compared to clopidogrel?

P

Population

Acute coronary syndrome (ACS) patients treated with percutaneous coronary intervention (PCI)

I

Intervention

Ticagrelor

C

Comparator

Clopidogrel

O

Outcome

Inflammatory parameters including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-high-density lipoprotein ratio (MHR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)surrogate

Ticagrelor may offer additional anti-inflammatory benefits over clopidogrel in patients with acute coronary syndrome undergoing PCI.

Abstract

NLR, MHR, PLR, and SII levels were lower in ACS patients treating with ticagrelor. Ticagrelor may improve these inflammatory parameters in percutaneous coronary intervention (PCI)-treated ACS patients compared to clopidogrel.

Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients

Structured PICO

Abstract

Cite This Study

Also Consider

Also Consider